Alternatives to Italy – Miscellaneous medical devices and products – P.A. DM STERILI E SISTEMI A CIRCUITO CHIUSO PER ALLESTIMENTO E SOMMINISTRAZIONE FARMACI ANTIBLASTICI, CITOTOSSICI E BIOLOGICI

Italy – Social work services – SUA PROV BG. PREFETTURA DI BG. SERVIZIO ACCOGLIENZA E ASSISTENZA CITTADINI STRANIERI RICHIEDENTI PROTEZIONE INTERNAZIONALE C/O CENTRI ART.11 D.LGS. 142/2015 UBICATI NEL TERRITORIO PROVINCIALE DI BG - SINGOLE UNITA' ABITATIVE CON CAPACITA' RICETTIVA MAX 50 POSTI PER STRUTTURA - TOTALE COMPLESSIVO DI N. 150 POSTI, PER LA DURATA TRIENNALE, INIZIO PRESUNTO DALLA DATA DI STIPULA.

Italy – Miscellaneous medical devices and products – Fornitura di dispositivi sterili in TNT (teli, camici e kit) per uso chirurgico e dispositivi medici in TNT ed accessori a corredo di kit chirurgici in TTR

Italy – Medical equipments – ACP3597PA - Fornitura in noleggio di macchine maceratrici (tritapadelle) con acquisto di materiale di consumo

Expected Outcome: Proposals submitted to this call are expected to address several of the following elements: • Scaling of wafer-level photonic processes for key materials (e.g. SiN, InP, GaAs),including process integration, yield optimisation, and manufacturability at highvolumes. • Development of packaging and test solutions that are scalable, automated, andcompatible with co-packaged optics and advanced photonic-electronic integration. • Integration of heterogeneous materials and components, such as on-chip lasers,modulators, and detectors, using advanced packaging and assembly approaches. • Design-process-equipment co-optimisation, enabling repeatable, cost-effectiveproduction of complex photonic circuits and systems, including use of PDKs andvalidated building blocks. • Demonstration of system-level functionality through application-relevant use casesin strategic sectors (e.g. AI, sensing, telecommunication, mobility, health, defence),with quantified performance metrics and clear market relevance.

Expected Outcome: the proposals under this call are expected to address one or more of the following subjects : • Enhanced personalized monitoring, care and treatments, focusing on the development of highly customized healthcare solutions, including the required research and diagnostic tools, tailored to individual needs, covering various scenarios such as chronic disease management, physiotherapy, precision diagnosis, personalized medicine/treatment, pre- and postoperative care, and daily assistance in homes and common spaces. It also targets effective management of chronic diseases and elderly care through personalized monitoring and interventions facilitated by advanced sensor technologies and edge-to-cloud solutions. This includes the development and integration of solutions for Hospitalization at Home, enabling patients to receive complex, remotely supervised care using intelligent medical devices capable of sensing, analysing, and transmitting real-time data. This requires a continuum, from in-hospital diagnostics to robust, long-term patient support at home via AI-driven care pathways and hospitalization at home. • Prevention and treatment of diseases, allowing the improved…

Provision of Non-Emergency Patient Transport Services (NEPTS) for GHFT. Additional information: GHFT (Gloucestershire Hospitals NHS Foundation Trust) "the Authority" invites Bidders to compete for the Provision of Non-Emergency Patient Transport Services (NEPTS) for GHFT. This procurement is being undertaken Provider Selection Regime which came into force on 1 January 2024. This Tender is only open all suppliers The Tender information can be found on the Trusts e-Portal (Atamis Health Family) at https://health-family.force.com/s/Welcome. Reference - C457853 You must be registered on the Atamis to view the Documents and all bids and communications must be submitted via this e-Portal. If you require any technical assistance using Atamis, please refer to the Supplier Portal user guide ( https://services.atamis.co.uk/docs/Supplier_User_Guide.pdf ) and/or the helpdesk on 0800 0988 201.

Sweden – Personal care products – Extern Remiss Hygien och städmaterial 2025

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…

Italy – Maintenance hangar construction work – Venaria Reale (TO) - Aeroporto M. Santi (ID 810) - Realizzazione di un nuovo hangar, piazzole e fabbricato servizi

Spain – Welfare services for children and young people – CONTRATACIÓN DE 74 PLAZAS DE ACOGIMIENTO RESIDENCIAL MENORES. MODALIDAD: VARIAS

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…